Personal Information
Ms. Rewa Ulhas Chaubal is a dynamic young entrepreneur and future Director of AIRMID Chemicals Private Limited (AIRMID). As a proud equity holder, she is dedicated to advancing INDIA's pharmaceutical and healthcare sector, fostering self-sufficiency and global leader.
After earning a Bachelor’s Degree in Chemistry from the University of Mumbai, INDIA, she pursued a Master’s in Organic Chemistry at the University of Leeds, UK. Her academic journey across Europe, provided invaluable exposure to International pharmaceutical markets enabling her to identify key opportunities for INDIA to emerge as a Global Leader in high-quality pharmaceutical solutions.
Guided by her vision, she established a sourcing services vertical within AIRMID, specializing in Reference Listed Drugs and Innovator Reference Standards. This initiative empowers INDIAN pharmaceutical companies to develop cost-effective, life-saving medicines, reinforcing INDIA's position in the Global Healthcare landscape.
With a strong commitment to innovation and excellence, she strives to bridge gaps, cultivate strategic partnerships and drive sustainable growth in the pharmaceutical industry.
Company Profile
AIRMID Chemicals (AIRMID) is a privately held company, established in 2021, as part of a distinguished pharmaceutical group with over two decades of industry expertise, registered under the Micro, Small and Medium Enterprises Development Act, 2006 (MSME Act) and is recognized as a startup by the Department for Promotion of Industry & Internal Trade (DPIIT). AIRMID is committed to the identification, development and commercial production of high-quality, INDIA-origin pharmaceutical excipients and cosmetic ingredients—offering a viable alternative to sourcing from China, Europe, and the USA.
Since its inception, AIRMID has successfully collaborated with local manufacturers to develop five internationally compliant ingredients, now qualified by leading pharmaceutical companies in INDIA. Driven by a strong commitment to self-reliance, AIRMID aims to establish a state-of-the-art Research & Development (R&D) Centre, and a dedicated production unit, by 2027.